Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
signs and symptoms pathological conditions | D013568 |
Brand Name | Status | Last Update |
---|---|---|
angiotensin ii | ANDA | 2025-06-04 |
giapreza | New Drug Application | 2024-11-26 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Angiotensin Ii Acetate, Giapreza, La Jolla Pharma | |||
11219662 | 2037-01-06 | U-3262 | |
9220745 | 2034-12-18 | U-2217, U-2218 | |
10028995 | 2034-12-18 | U-2338 | |
10493124 | 2034-12-18 | U-2679 | |
11096983 | 2034-12-18 | U-3211, U-3212 | |
11559559 | 2034-12-18 | U-3514 | |
9572856 | 2031-07-18 | U-2221 | |
9867863 | 2029-12-16 | U-2231 | |
10335451 | 2029-12-16 | U-2581 | |
10500247 | 2029-12-16 | U-2680, U-2681 | |
10548943 | 2029-12-16 | U-2739, U-2740 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 1 | 4 | 40 | 24 | 32 | 101 |
Healthy volunteers/patients | — | — | — | 35 | — | — | 1 | — | 36 |
Essential hypertension | D000075222 | — | I10 | — | 1 | 5 | 1 | 3 | 10 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 3 | 3 | — | 6 |
Isolated systolic hypertension | D000092244 | — | — | — | — | 1 | 1 | 1 | 3 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | 2 | — | 3 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 1 | 2 | — | 3 |
Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | — | 3 | — | 3 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | 1 | 1 | 2 |
Renal insufficiency | D051437 | — | N19 | — | — | 1 | 1 | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Systolic murmurs | D054160 | — | R01.1 | — | — | 1 | — | 1 | 2 |
Polycystic kidney diseases | D007690 | — | Q61.3 | — | — | 2 | — | — | 2 |
Dyslipidemias | D050171 | — | — | — | — | 1 | — | — | 1 |
Chronic renal insufficiency | D051436 | — | N18 | — | — | 1 | — | — | 1 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | 1 | — | — | 1 |
Disease progression | D018450 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | — | 1 |
Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | 1 | — | — | — | 1 |
Overweight | D050177 | — | E66.3 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | — | 1 |
Fatty liver | D005234 | EFO_0003934 | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 1 | 1 |
Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | — | — | 1 | 1 |
Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
Drug common name | Angiotensin ii |
INN | angiotensin ii |
Description | Ile(5)-angiotensin II is an angiotensin II that acts on the central nervous system (PDB entry: 1N9V). It has a role as a human metabolite. It is a tautomer of an Ile(5)-angiotensin II dizwitterion. |
Classification | Protein |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O |
PDB | — |
CAS-ID | 11128-99-7 |
RxCUI | — |
ChEMBL ID | CHEMBL408403 |
ChEBI ID | 2719 |
PubChem CID | — |
DrugBank | — |
UNII ID | M089EFU921 (ChemIDplus, GSRS) |